BOWIE, Md. – February 11, 2015 – Inovalon, a leading technology company providing advanced cloud-based data analytics and data-driven intervention platforms to the health care industry, today announced the pricing of its initial public offering of 22,222,222 shares of its Class A common stock at a price to the public of $27.00 per share, $1.00 above the filing range of $24.00 to $26.00 (a range which was revised upwards from the initial filing range of $21.00 to $24.00). In addition, Inovalon has granted the underwriters a 30-day option to purchase up to 3,333,333 additional shares of Class A common stock at the initial public offering price. The shares are expected to begin trading on the NASDAQ Global Select Market on Feb. 12, 2015, under the ticker symbol “INOV.”
Goldman, Sachs & Co., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. are acting as joint lead book-running managers, BofA Merrill Lynch and UBS Investment Bank are also acting as book-running managers for the offering. Robert W. Baird & Co., Piper Jaffray & Co., Wells Fargo Securities, LLC and William Blair & Company, LLC are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 11, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from: Goldman Sachs Prospectus Department, 200 West Street, New York, NY 10282, by email at email@example.com, by fascimile at 212-902-9316 or by phone: 1-866-471-2526; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street 2nd Floor New York, New York 10014, or by phone: (866) 718-1649; Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue Edgewood, New York 11717, by email at firstname.lastname@example.org, or by phone: 1(800) 831-9146; BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, by email at email@example.com, or by phone: (212) 449-1000; UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue New York, New York 10171, or by phone: 1(888) 827-7275.
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Inovalon’s unique achievement of value is delivered through the effective progression of Turning Data into Insight, and Insight into Action®. Large proprietary datasets, advanced integration technologies, sophisticated predictive analytics, and deep subject matter expertise deliver a seamless, end-to-end platform of technology and nationwide operations that bring the benefits of big data and large-scale analytics to the point of care. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while bringing to bear the unique capabilities to resolve them. Supporting hundreds of healthcare organizations in 98.2% of U.S. counties and Puerto Rico, Inovalon’s analytical and data-driven intervention platforms are informed by data pertaining to more than 754,000 physicians, 248,000 clinical facilities, and more than 120 million Americans providing a powerful solution suite that drives high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, patients and researchers.
Kim E. Collins
4321 Collington Road
Bowie, Maryland 20716
Phone: 301-809-4000 x1473
on behalf of Inovalon